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ABSTRACT 
Objective. To carry out a pharmacoeconomic analysis of Cyclamen europaeum 
(CE) in the management of acute rhinosinusitis (ARS) in Spain using data from the 
PROSINUS study. 
Study Design. This was a prospective observational study to compare the 
effectiveness and cost-effectiveness between therapies including CE vs. other 
therapies in the management of ARS. 
Methods. The study was carried out as a secondary analysis of the PROSINUS, 
combining healthcare resource use, productivity loses, and health outcomes from 
the observational study with costs representative of the Spanish Health System. 
Results. CE given as monotherapy appears to be more effective (cure rate) than 
other monotherapies (15.3% higher, p<0.05) and combination (10.3% higher, 
p<0.05) therapies. The addition of CE to other single-drug or combination therapies 
showed a statistically significant improvement in terms of cure rates when adding 
CE to 2-drug combinations (93.9% vs. 76.5%; p<0.05), and no significant effect 
when added to combinations of three or more drugs (81.1% vs. 79.8; NS). CE-
based therapies generally showed lower indirect costs, although only the 
comparison of CE alone vs. other monotherapies, with a net cost savings of 101€ 
per patient, reached statistical significance (331€ vs. 432€, p<0.05). In addition, 
CE-based therapies show lower cost per cured patient in all comparisons except 
when CE was used in combination with three or more other drugs. 
Conclusions. The use of Cyclamen europaeum may be associated to better 
clinical outcomes at no additional cost for the healthcare system, respect to 
treatments commonly used for ARS in clinical practice. 
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INTRODUCTION 
 
Rhinosinusitis is an inflammatory process of the paranasal sinuses with high 
prevalence in clinical practice1,2. Acute rhinosinusitis (ARS) is an inflammatory 
alteration of the nose and paranasal sinuses. ARS is usually caused by a viral 
infection, although other processes such allergic rhinitis, pathological 
abnormalities, nasal polyps, or nasal decongestant abuse, can constitute 
predisposing factors. Inflammation in nasal cavity mucosa results in some 
disorders of the absorption, protection and transport functions, and complications 
like asthma flare-ups, chronification of ARS, meningitis, vision problems and ear 
infections. In ARS the most common symptoms experienced by patients are nasal 
obstruction, mucopurulent rhinorrhoea, and localized frontal or facial pain.  
It is currently accepted that ARS is a frequent disease and, therefore, has a 
considerable impact on general public health and economic resources, both in 
terms of those allotted to treatment disease as well as those related to patient labor 
productivity. In the United States, it was estimated that in 1996 the costs that could 
be attributable to rhinosinusitis reached 3,390 million dollars3. The number of 
cases in Spain could range between 440,000 and 1,760,000 per year, with a 
considerable associated cost2.  
ARS treatment goals should be symptomatic relief, accelerating remission and 
preventing complications. Indeed, there is a weak body of clinical evidence about 
treatment effectiveness and controlled clinical trials of ARS therapies are not 
numerous4. Most authors and consensus papers show little evidence on the 
effectiveness of treatments based on antibiotics5, oral steroids6, antihistamines, 
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nasal irrigation, mucolytics and phytotherapy7. The treatment recommended for 
ARS by the EPOS consensus (European Position Paper on Rhinosinusitis and 
Nasal Polyps)7 is based on symptomatic relief (analgesics, saline serum and 
decongestants) or on the use of topical nasal steroids and antibiotics for the 
specific patients that can respond, depending on the etiology, severity and 
evolution of the clinical pattern8. Upon analyzing evidence of adjuvant treatment 
aimed to relief symptoms, it can be concluded that it is low. In Spain, the 
PROSINUS study9 a large observational study showed that less than one fourth 
(24%) of 2,610 patients with ARS followed EPOS guidelines, and a number of 
different treatments and drug combinations were used.  
 
Cyclamen europaeum has been used for a very long time, particularly in South-
East Europe, as a traditional treatment for nasopharyngeal diseases. Cyclamen 
europaeum (CE) is prepared on the basis of an aqueous extract of tubers of CE, 
that contain a mixture of saponins, which characteristically causes local osmosis 
and stimulation of the ending terminal of the trigemin and increases the secretion 
of the nasal mucos10, 11. CE has shown its efficacy in two placebo-controlled clinical 
trial and 13 head to head studies (9 in adults and 5 in children) that compared CE 
with other active treatments that seem to indicate that CE may contribute to 
reducing disease progression time, improving symptoms relief and objective 
response (CT-scan), decreasing the need for antibiotics or boosting their effects, 
as well as reducing the number of complications and chronification12. 
 
The present study has analysed data from the PROSINUS study to carry out a 
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pharmacoeconomic analysis of CE in the management of ARS in Spain. 
 
 
MATERIALS AND METHODS 
 
Subjects 
 
The PROSINUS study included 2,610 patients visited by 287 specialists in 
otorhinolaryngology throughout Spain. Patients had to fulfil all inclusion criteria: 
either sex, ≥18 years of age, reporting to the otorhinolaryngologist’s office with 
symptoms compatible with the epidemiological diagnosis of ARS according to the 
EPOS consensus “sudden onset of two or more symptoms, one of which should be 
either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior 
nasal drip), ± facial pain/pressure, ± reduction or loss of smell; for a duration of <12 
weeks”. Patients voluntarily gave their consent to take part in this study and they 
had none of the exclusion criteria: established diagnosis of chronic rhinosinusitis 
(with or without nasal polyps, and presenting with a new event or acute 
exacerbation of their disease), concurrent use of medication for other conditions 
that could interfere with the sinonasal disease, existing social or cognitive features 
indicating the possibility of problems in the follow-up or a high risk of withdrawing 
prematurely from the study. Data on the previous management by Primary Care 
Physicians was also recorded.  
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Study design 
 
The PROSINUS study was an epidemiological, observational, prospective, health 
outcomes study aimed to describe the diagnostic, treatment and clinical monitoring 
procedures applied in ARS in clinical practice in Spain. Since this was an 
observational study aimed at identifying current practice real failure rates, and 
costs associated with usual medical care and not under experimental conditions, 
treatment of the ARS was left to the criteria of the attending physician. The present 
study was carried out as a secondary analysis of the PROSINUS database, 
combining healthcare resource use, productivity loses and health outcomes from 
the observational study with updated unit costs representative of the Spanish 
National Health System (SNHS). Data for both clinical and economic variables (see 
below) were recorded prospectively by the investigators (from symptoms onset 
until first study visit, and from first study visit to final study visit, 2 to 4 weeks after 
first visit). 
 
Comparative options 
 
Costs and outcomes of CE in monotherapy and combination therapy were 
compared to both monotherapies and combinations therapies as follows: 
 • CE in monotherapy vs. other pooled monotherapies and vs. combinations of 
two or more pooled drug combinations without CE. 
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 • CE added to different combinations, specifically: CE added to one single 
drug, CE added to two drug combination, and CE added to three or more 
combined drugs. 
 
Additional analysis was carried out to address the effect of adding CE to antibiotics 
and antibiotics + corticosteroids8. 
 
In all cases, comparison options were defined by means of the treatments 
prescribed by the patients at the first visit of the study, irrespective of treatments 
taken previously (from event onset to first physician visit). 
 
Clinical outcomes 
 
Cure rate was defined following the EPOS consensus for epidemiological 
definition7 as the complete clinical resolution of ARS symptoms of the ARS episode 
at the end of the study follow-up (visit 2 at 2-4 weeks) and was calculated for each 
comparison option. For the primary analysis, the patient sample that met all of the 
inclusion criteria and none of the exclusion criteria and which had valid data for the 
primary endpoint was used. No provision was made for interpolating missing data o 
loss to follow-up. 
 
Economic outcomes 
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Both direct and indirect costs were included in the analysis. Direct costs included 
medical visits (general practitioner, otorhinolaryngologist and emergency visits), 
diagnostic tests (rhinoscopy or nasal endoscopy, sinus X-ray, sinus CT, bacteria 
culture and allergy tests) and drugs (oral antibiotics, nasal corticosteroids, 
antihistamines, nasal decongestants, mucolytics, saline solutions, and 
phytotherapy including CE). Indirect costs included sick leaves (absenteeism) and 
reduced productivity at work (presenteeism). In the PROSINUS study, resources 
use from the onset of the ARS event to the date of the visit was also recorded at 
the first study visit. At the second visit, resources uses from first visit to the end of 
the event were recorded. Thus, otorhinolaryngologists could have influence in the 
resources use after but not before the first visit since symptoms onset.  
 
Unit costs applied to the health resources utilization data are shown in Table 1. 
The data sources were the Medicine Database of the General Council of 
Pharmacists Official Colleges (BOTPLUS)13 for drug costs, and the Health Costs 
Database eSalud14 for healthcare resources (medical visits and tests). With respect 
to the medication, it was assumed that a patient would purchase one pack of each 
type of drug that he/she used. All costs were expressed in euros of 2011. 
 
Perspective, time horizon and discount rate 
 
The main analysis was carried out from the societal perspective (including both 
direct and indirect costs). Additional analysis adopted the healthcare perspective 
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(direct costs only). Since study follow-up was short (1 month) no discounting was 
applied in the analysis. 
 
Statistical Analysis 
 
Statistical analysis was performed with SPSS version 15.0 for Windows (SPSS 
Inc., Illinois, USA). ANOVA was carried out to see if there was any difference 
between subgroups and logistic regression models were built to determine whether 
specific drugs had a significant influence in the cure rate of pooled options, to 
discard relevant heterogeneity of comparison options in the analysis. 
Student's t-test and CHI-square test were used to compare mean costs and cure 
rates of CE-based therapies respect to comparators. The level of statistical 
significance was established at 0.05. 
 
RESULTS 
 
On average, patients reported to the first PROSINUS study visit 11.2 (±6.2) days 
after onset of the ARS event, while the average total duration of the event was 13.7 
(±8.8) days. At visit 2, 82.9% of patients presented complete clinical resolution of 
the symptomatic episode. Table 2 shows the clinical results of the comparison of 
CE based therapies respect to other therapies in the management of ARS. CE in 
monotherapy appeared to be more effective in terms of cure rate than other pooled 
monotherapies (15.3% higher, p<0.05) and combination therapies (10.3% higher, 
p<0.05). The addition of CE to other monotherapies or combination therapies 
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showed a significant improvement when adding CE to 2-drug combinations (93.9% 
vs. 76.5%; p<0.05), but no significant effect when added to combinations of three 
or more drugs (81.1% vs. 79.8%; NS).  
 
Patients receiving CE monotherapy were 98€ less costly than patients receiving 
other monotherapies (682€ vs. 584€, p<0.05) and 61€ less costly than combination 
therapies (645€ vs. 584€, p<0.05). Figure 1 show the breakdown of these results in 
terms of direct and indirect costs. CE as an add-on treatment was associated to 
lower total costs when used in combination with one single drug (626€ vs. 682€, 
p=0.29), even though these differences didn’t reach the statistical significance, 
probably because of the limited sample size. The combination of CE with 2 or more 
drugs produced similar total costs than the same combinations without CE. In all 
situations, cost reductions associated to CE-based therapies were mainly 
explained by indirect costs, whilst direct healthcare costs were similar in all 
subgroups (see table 3). The proportion of patients treated with CE that were 
visited by PCP or PCP and ORL was slightly higher than for patients not taking CE, 
but differences were only significant vs patients treated with antibiotics (which 
accounted for a small subgroup of patients). This fact could yield to higher costs for 
CE patients but this is not the case because of the lower number of total visits in 
this group. 
The combination of total costs and cure rates provides an estimate of the balance 
between cost and outcomes, showing lower cost per cured patient in CE  based 
therapies in almost all comparisons (except when added to combinations of 3 or 
more drugs) (Figure 2). 
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Special situations 
 
Since only antibiotics, either in monotherapy or combined with corticosteroids have 
demonstrated a clinical efficacy in the management of ARS, a specific analysis 
was carried out to compare these options with and without CE. The results of this 
analysis showed that adding CE to one antibiotic, with or without nasal 
corticosteroid, increased the success rate and reduced total costs, due to a 
significant reduction of indirect costs. Both compared to antibiotic in monotherapy 
or to antibiotic plus nasal corticoid, the addition of CE resulted in a lower cost per 
success ratio (table 4). 
 
 
DISCUSSION 
 
This secondary analysis of the PROSINUS study, an observational, prospective, 
health outcomes study aimed to describe the management of ARS and its 
outcomes, has shown that CE based therapies are associated to better clinical 
outcomes with similar or even lower costs than comparable therapies without CE.  
 
These results are in line with the conclusions of most of the clinical studies on 
ARS, including placebo-controlled clinical trials and head to head clinical studies. 
Pfaar et al., in a randomized controlled trial in patients with moderate-to-severe 
ARS, demonstrated that CE on the top of regular antibiotic treatment added a 
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significant improvement of facial pain/pressure and signs of nasal inflammation 
compared to antibiotic alone12. CE is a safe and well tolerated treatment that 
demonstrated a great reduction in individual symptoms scores (nasal obstruction, 
mucus secretion, facial pain and loss of smell), an improvement in the mucosal 
edema and nasal obstruction evaluated by endoscopy and a reduction of the sinus 
occlusion evaluated by CT-can on day 715. The effects of CE on ARS start at 3-5 
days of treatment and the complete symptom resolution at 9-12 day15. CE was able 
to reduce the disease progression time, the need for antibiotics or boosting their 
effects, the number of complications and the disease chronification with a great 
satisfaction scores rated by patients and investigators compared to antibiotic 
treatment12. Several drugs, like antibiotics, oral decongestants, antihistamines, and 
topical corticosteroids are used for the treatment of RS but these available 
therapies don’t have sufficient evidence to be considered efficacious and often fail 
to provide adequate symptoms relief and or objective cure assessed by endoscopy 
or CT-scan. Consequently, patients with ARS are often poorly treated and / or 
treated using several therapies. Despite continued d velopment of new therapies 
and more accurate diagnostic procedures, there is no evidence that ARS is being 
better controlled. CE could be considered a recommendable option as a first line 
treatment as it has demonstrated in several clinical studies its ability improving the 
signs and symptoms of the disease. Besides, Savvateeva and Lopatin16 have 
recently published a review of studies that evaluated the efficacy and safety of CE 
and concluded that it provides a good option for ARS treatment, ensuring 
personalized treatment and preventing polymedication and inappropriate use of 
antibiotics. 
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As ARS frequently occurs in conjunction with asthma, allergic rhinitis, and other 
airway disorders, it is difficult to single out the expenditures devoted to treating 
rhinosinusitis only, and only a few studies have done so17 and results are notably 
variable. Anzai et al.18 examined the cost-effectiveness of four treatment strategies, 
with and without antibiotics, for adult patients with acute sinusitis, finding a total 
cost per patient between $747 and $899 in 2005. Bhattacharyya et al.19, 20 have 
recently published two studies of the burden of rhinosinusitis (recurrent ARS and 
chronic rhinosinusitis respectively), with total cost per patient/year of $1,091 and 
$780. These results are hardly comparable with those from our study, since we 
focused in costs associated to a single ARS event, whilst those mentioned studies 
analysed longer time horizons. Finally, pharmacoeconomic analysis of two 
antibiotic therapies found a direct healthcare cost per ARS episode of $171-$211 in 
200221, slightly lower than our estimates of 250€-329€. 
 
Given the high prevalence of ARS and the eventual consequences of treatment 
failure, including potential disease chronification, clinical success should be 
pursued in order not only to improve patients’ quality of life but to limiting the 
economic impact of the condition.  
In our study the use of CE was associated to a higher cure rate without increasing 
healthcare costs, either when compared as monotherapy respect to other 
monotherapies, or when added to different combinations.  It is important to note 
that not properly treated rhinosinusitis could lead to a recurrence or even to a 
potential chronification of the disease whereas consequently reducing patient's 
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overall well-being and quality of life and increasing direct and indirect costs19. 
Therefore, in this sense cyclamen provides an added value because reduces 
chronification of ARS. Besides, cyclamen has a purely physiological effect and is 
not absorbed, showing a better safety profile compared to other treatments that 
cause more or worse adverse events and consequently produce a greater cost 
derived from adverse event management22. 
 
This study has two main limitations that must be considered. First, the use of the 
data from an observational descriptive study to derive conclusions regarding the 
consequences of different treatment options is risky, i.e., the PROSINUS study 
was not designed to compare different therapies, and patients’ characteristics may 
be assumed equivalent irrespective of treatment received, so a selection bias could 
exist. Considering  the ethical  and  logistical  weaknesses of randomised clinical 
trials,  well  designed  and  conducted  observational  studies  may be an efficient 
alternative to  explore  exposure  effectiveness, even though  comparability  
across  exposure  groups  may not be  guaranteed. Second, the comparison 
options built in the secondary analysis include the outcomes of patients that 
received different drugs in different combinations, e.g., the pooled results of CE vs. 
other monotherapies included a number of different drugs in the group ‘other 
monotherapies’. However, logistic regression techniques were applied to address 
whether this pooling of clinical results were justifiable, i.e., no statistical differences 
between individual treatments (or combinations) were stated before aggregating 
patients in the pool analysis. These limitations raise the need for further research 
to definitely establish the clinical superiority of Cyclamen in different clinical 
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situations and combined with different treatments. 
 
Finally, it is noteworthy that the present study is pragmatic and widely applicable in 
clinical practice, and although it has the mentioned limitations, especially in relation 
to the selection of treatments, we can conclude that the trend Cyclamen 
europaeum has in monotherapy for ARS is cost efficient. However, further studies 
are needed with greater control in order to conclude on the effect of cyclamen with 
other treatment combinations of ARS.. 
 
 
CONCLUSIONS 
 
The results of this study suggest that the use of CE, both as monotherapy or in 
combination, may be associated to better clinical outcomes, including cure rate, at 
no additional cost for the healthcare system, respect to different treatment options 
commonly used in clinical practice for the treatment of ARS. 
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Figure 1. Results of the cost analysis – CE monotherapy vs other monotherapies 
(pooled) and combinations 
 
Figure 2. Total cost per cured patient 
Legend: CE: Cyclamen europaeum 
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Table 1. Unit costs used in the analysis 
Item Cost (€) 
Drug Cost (per package) 
Oral antibiotics 16.30 
Nasal corticosteroids 14.59 
Antihistamines 9.48 
Descongestants 4.56 
Mucolytics 4.31 
Saline solutions 2.20 
Phytotherapy (including CE) 26.00 
Cost of diagnostic tests (per procedure)  
Sinus X-ray  8.00 
Sinus CT 87.60 
Bacterial culture  10.50 
Allergy tests (per procedure)  64.80 
Cost per visit 
Emergency at Primary Care Centre  50.10 
Primary care physician 33.40 
Otorhinolaryngologist (1st  visit)  103.65 
Otorhinolaryngologist (subsequent visit) 44.60 
Other specialists 44.60 
Sources: BOTPLUS 2011, eSalud 2011. CE: Cyclamen europaeum; CT: 
computerized tomography 
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Table 2. Cure rates of Cyclamen-based options vs. other treatment options 
(comparators). 
Comparison 
Cyclamen 
% mean (SD) 
Comparator 
% mean (SD) 
Difference 
% 
p-value 
Cyclamen 
monotherapy 
(n=90) vs. 
Other 
monotherapies 
(pooled) (n=68) 
88.8 (31.8) 73.5 (44.4) +15.3 <0.05 
Cyclamen 
monotherapy 
(n=90) vs. 
Other 
combinations 
(pooled) 
(n=221) 
88.8 (31.8) 78.5 (41.1) +10.3 <0.05 
Cyclamen 
(n=61) + 1 drug 
(pooled) vs. 1 
single drug 
(pooled) (n=68) 
81.7 (39.0) 73.5 (44.4) +8.2 NS 
Cyclamen 
(n=82) + 2 
drugs 
combinations 
(pooled) vs. 2 
drugs 
combinations 
(pooled) (n=87) 
93.9 (24.1) 76.5 (42.7) +17.4 <0.05 
Cyclamen + 3 
or more drug 
combinations 
(pooled) (n=86) 
vs. 3 or more 
drug 
combinations 
(pooled) 
(n=134) 
81.1 (40.0) 79.8 (39.0) +1.3 NS 
NS: non-significant; SD: standard deviation 
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Table 3. Results of the cost analysis. CE in combination 
 
  
1 single drug  
(n=68) 
Cyclamen + 1 
drug (n=61) 
Difference p-value 
Total costs, mean 
(SD) 
682 € (233 €) 626 € (359 €) -56 € NS 
Direct 250 € (135 €) 269 € (108 €) +19 € NS 
Indirect 432 € (193 €) 357 € (328 €) -75 € NS 
  
 
2 drugs  
(n=87) 
 
Cyclamen  
+ 2 drugs (n=82) 
Difference p-value 
Total costs, mean 
(SD) 
628 € (235 €) 629 € (245 €) +1 € NS 
Direct Costs 258 € (SD 107 €) 290 € (SD 89 €) +32 € NS 
Indirect Costs 370 € (SD 205 €) 339 € (SD 209 €)  -31 € NS 
  
 
3 or more drugs 
(n=134) 
 
Cyclamen + 3 or 
more drugs 
(n=86) 
Difference p-value 
Total costs, mean 
(SD) 
656 € (1089 €)  691 € (263 €) +34 € NS 
Direct Costs 278 € (182 €)  329 € (464 €) +50 € NS 
Indirect Costs 378 € (616 €) 362 € (367 €) -16 € NS 
NS: non-significant; SD: standard deviation 
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Table 4. Costs and outcomes of adding CE to antibiotic with or without 
corticosteroids 
  
Antibiotic  
(n=14) 
CE + Antibiotic 
 (n=24) 
Difference p-value 
      
Total costs, mean (SD) 686 € (233 €) 479 € (261 €) -206 € <0.05 
Direct 247 € (97 €) 255 € (117 €) +8 € NS 
Indirect 439 € (201 €) 224 € (223 €) -214 € <0.05 
Cure rate, mean (SD) 60.0% (50.7) 91.3% (28.8) +31.3% NS 
Cost per cured patient 1.143 € 525 €   
 
 
 
Antibiotic + 
Corticosteroid 
(n=14) 
 
 
CE + Antibiotic + 
Corticosteroid 
 (n=19) 
Difference p-value 
     
Total costs, mean (SD) 648 € (194 €) 650 € (182 €) +2 € NS 
Direct 292 € (95 €) 292 € (57 €) 0 € NS 
Indirect 355 € (356 €) 358 € (187 €) -2 € NS 
Cure rate, mean (SD) 57.0% (51.0) 100% (0)   
Cost per cured patient 1.134 € (816 €)   650 € (182 €)   
 
NS: non-significant; SD: standard deviation. 
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Results of the cost analysis – CE monotherapy vs other monotherapies (pooled) and combinations.  
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Total cost per cured patient/CE: Cyclamen europaeum  
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